In HRR-deficient cells, such as CML, PARPi treatment in combination with METTL3 inactivation may induce a "synthetic lethality" effect, where the combined inhibition of two DNA repair pathways becomes lethal to the cancer cells. The gene discussed is METTL3; the disease is cancer.